340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)

Join Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the editor of Drug Channels, for his latest exclusive video webinar:

340B in 2026: Market Shifts, Policy Battles,
and What They Mean for Stakeholders

This event will be broadcast live on:
Friday, June 12, 2026
12:00 p.m. to 1:30 p.m. ET

Register Now

Dr. Fein will be joined by Tyler Novotny, MBA, the SVP at DCI.

The webinar will be broadcast live from the Drug Channels studio in beautiful downtown Philadelphia. It is part of The Drug Channels 2026 Video Webinar Series.

Jump to:

• What You Will Learn
• Pricing Options
• Important Things To Know

WHAT YOU WILL LEARN

Join industry expert Adam J. Fein, Ph.D., and his colleague Tyler Novotny, MBA, for an exclusive deep dive into the 340B Drug Pricing Program—one of the most complex and controversial segments of the U.S. pharmaceutical market.

In this all-new webinar, Adam and Tyler will deliver a fact-based, data-driven analysis of the 340B program’s structure, economics, and rapid evolution. He’ll unpack the key controversies reshaping the program, explain what’s really happening behind the headlines, and provide a clear, actionable outlook for stakeholders across the drug channel.

Whether you’re in pharma, provider organizations, pharmacy, or policy, you’ll gain the insights needed to understand where 340B is headed—and what it means for your business.

Key topics include:

• The structure and economics of the 340B program

• Growth trends among covered entities and their partners

• 340B’s expanding role in pharmacy—and its impact on PBMs and retail

• DCI’s latest data on the contract pharmacy marketplace and the leading participants

• The role of third-party administrators and vendors in the 340B ecosystem

• What’s behind the growing controversy over the definition of an eligible patient

• Why diversion and duplicate discounts have become flashpoints

• The implications of the Net Pricing Drug Channel for 340B pricing dynamics

• How 340B funds are generated and distributed across participating entities

• How employers and plan sponsors could reshape the program’s future

• Manufacturers’ evolving distribution strategies for 340B contract pharmacies

• Recent legal developments affecting manufacturer policies and contract pharmacy arrangements

• The expanding influence of state legislation

• The impact of the Inflation Reduction Act on program operations and oversight

• The HRSA vs. CMS oversight crisis

• The outlook for a potential 340B rebate model

• What’s ahead for state and federal policy

• Emerging risks, challenges, and threats to watch

Plus: fresh insights and expert perspective you won’t find anywhere else.

As always, they will clearly distinguish their opinions and interpretations from the objective facts and data.

This 90-minute video webinar will feature a dedicated Q&A session, where attendees can unmute and engage directly with Tyler and Adam.

Register now to stay informed and get ahead of the curve on 340B!

PRICING OPTIONS

Take advantage of this exclusive educational opportunity for just $420 per viewing device. Once you register, you'll receive a unique Zoom access link within 24 hours—making it easy to add the event to your calendar and ensure you don’t miss out.

Special Discounts For Teams!

We understand that many professionals are working remotely, so we’re offering substantial savings for multiple registrations from the same organization. What's more, an unlimited number of attendees can watch together at a single physical location with one registered device.

Important Reminder: Each device at a single physical location must have its own registration. The webinar may not be recorded, streamed, broadcast, or shared across different locations, devices, or sites.

Click here to register. All discounts will be automatically computed based on the number of registrations you enter in your cart. (You can reset the cart by entering 0 in the quantity field.)

340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders

Questions about corporate pricing? Please contact Marie Caldwell (mcaldwell@hmpglobal.com).

Purchasing access for multiple sites? We'll contact you for your participant list. Or, download this spreadsheet and email your registrants’ information to dcisupport@hmpglobal.com.

Payment can be made with all major credit cards (Visa, MasterCard, American Express, and Discover). Prefer check or ACH? Click here to request an invoice.

IMPORTANT THINGS TO KNOW

• Watch and listen via any modern browser via computer, tablet, or mobile. (No telephone access.)

• Each registrant will receive an email with a link to watch the event. This link is unique to the registrant and can only be accessed once.

• Every registrant will also receive a link to download Dr. Fein's slides.

• This event is part of The Drug Channels 2026 Video Webinar Series. If you already purchased access to the 2026 Drug Channels Video Webinar Series, then you already should have received an email from Zoom with a link to access the June 12, 2026, event.

• Organizations that purchased corporate access for The Drug Channels 2026 Video Webinar Series will receive a custom, branded signup link so employees can easily register. We will automatically refund payments from anyone at a company with corporate access who purchases a single registration using their corporate email account.

• Each registration for a DCI webinar is valid for a single device at a single physical location. Each device at a physical location requires its own registration. Attendees are not permitted to record, stream, share, or project a DCI webinar to other sites or locations. Purchasers who violate this limitation by recording, streaming, sharing, or projecting a DCI webinar to other sites, devices, or locations will be liable for the full cost of all locations that viewed the webinar. DCI reserves the right to prohibit purchasers who violate our terms from attending future DCI webinars.

• Unfortunately, we are unable to offer refunds.

The Hidden Costs of Over-Customizing Your Hub Technology Stack

Today’s guest post comes from George Moore, Chief Product and Technology Officer at CareMetx.

George argues that customer relationship management (CRM) program customization delivers short-term workflow gains at the expense of long-term scalability, integration simplicity, and upgradeability. He highlights three common pitfalls and offers an approach on how to avoid them.

To learn more, download CareMetx’s Guide to Building an Agile, Scalable Hub Architecture.

Read on for George’s insights.

Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point

By Adam J. Fein, Ph.D.

The Drug Channels Institute (DCI) team attended Asembia’s AXS26 Summit last week. Once again, the specialty pharmacy market delivered a classic paradox: a sprawling, fragmented landscape of participants paired with highly concentrated economics controlled by a handful of PBM-affiliated giants.

Below, we share our proprietary analyses of the specialty market’s participants. DCI identified more than 1,900 pharmacy locations that have achieved specialty pharmacy accreditation from one of the two major independent accreditation organizations.

Despite growing revenues from specialty drugs, overall growth in accredited pharmacies has plateaued. However, pharmacy locations owned by healthcare providers—hospitals, health systems, physician practices, and other healthcare providers—continue to expand and now account for nearly 40% of all accredited specialty pharmacy locations.

Read on for a bit of our arithmomania. Because in specialty pharmacy, what gets counted reveals who really counts.

Where Gross-to-net Pressure Actually Lives After Launch

Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Cindy explains that many gross-to-net (GTN) exposures now occur at the claim level, where evolving payer tactics, pharmacy economics, and copay complexity create unpredictable leakage. She argues that manufacturers must augment downstream review with real-time visibility and intervention to protect both revenue and patient access.

To learn more, register for ConnectiveRx’s free webinar on June 17: Gross-To-Net FOMO: What GTN Dangers Are You Missing Post-Launch?

Read on for Cindy’s insights.

Drug Channels News Roundup, April 2026: PBM Specialty Pharmacy Steering, MLR Profit Shifting, Hospitals’ Fake Prices, and a Peek Behind the Scenes at DCI

By Adam J. Fein, Ph.D.

Spring has officially arrived at Drug Channels' worldwide headquarters in beautiful downtown Philadelphia. (Photo proof at right.) So, dive into this month’s curated crop of noteworthy news:

• The patient experience at PBM-affiliated specialty pharmacies

• New evidence of profit shifting in vertically integrated Part D businesses

• The growing gap between non-profit hospitals’ public mission and financial reality

Plus: Behind-the-scenes at DCI

P.S. Join my nearly 70,000 LinkedIn followers for links to neat stuff, along with unfiltered commentary from the DCI community.

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Direct at GoodRx.

Laura suggests that manufacturers must move beyond payer-centric models toward integrated, direct-to-consumer and employer channel strategies that connect pricing, demand, and fulfillment. She argues that this approach will help manufacturers convert patient intent into therapy initiation while expanding access at scale.

To learn more about GoodRx’s pharma solutions, visit GoodRx Pharma Direct.

Read on for Laura’s insights.

Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care

By Bryce Platt, PharmD

Minnesota’s new 340B data reveal a growing disconnect between the program’s size and the value Minnesotans receive in return.

In 2024, nonprofit hospitals generated more than $1.3 billion in 340B net profits—nearly a billion dollars more than they provided in uncompensated care. At the same time, these same institutions already benefit from substantial tax exemptions tied to their not-for-profit status and charitable mission.

The gap between 340B profits and charity care isn’t a rounding error or a one-off anomaly. The 340B Drug Pricing Program has evolved into a significant profit center for hospital systems. This is another layer on top of existing public subsidies, not a substitute for them.

As you’ll see below, our analysis describes a 340B program that generates financial gains far in excess of any contribution back to the people of the state. There is also no clear accountability for how those dollars are used.

The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground

By Adam J. Fein, Ph.D.

Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs.

For 2025, DCI has identified more than 1,900 dispensing locations with specialty pharmacy accreditation from one or both of the two major independent accreditation organizations. The overall number of accredited locations grew by only 3% in 2025, but is more than five times larger than the 2015 figure.

However, market share for the dispensing of specialty drugs remains highly concentrated. For 2025, the three largest specialty pharmacies accounted for two-thirds of total prescription revenues from pharmacy-dispensed specialty drugs. These businesses are all owned by vertically integrated organizations that also own a PBM.

Below, we share DCI’s latest analysis of the top 15 specialty pharmacies, including updated market shares and revenue estimates, highlighting how vertical integration and channel control continue to reshape specialty dispensing. Despite growth in accredited locations, economic power remains concentrated among a small group of PBM-affiliated entities.

Next week, the DCI team will be attending Asembia’s AXS26 Summit in fabulous Las Vegas. Please say hello if you see us!

The Omnichannel Gap: Building the CRM of the Future for Patient Services

Today’s guest post comes from Karishma Desai, Associate Director of Data Strategy at Claritas Rx.

Karishma explains how the complexities of specialty therapies require a customer relationship management (CRM) system that unifies consent management. She goes on to explain that by embedding AI into the patient journey, automating workflows at scale, and enhancing collaboration among stakeholders, organizations can reduce delays, improve adherence, and deliver better patient outcomes.

To learn more, download Claritas Rx’s white paper: The Omnichannel Gap: Building the CRM of the Future for Patient Services.

Read on for Karishma's insights.

The Hidden Pitfalls of Hub Transitions—and How to Navigate Them

Today’s guest post comes from Brok Vandersteen, Vice President of Business Development at AssistRx.

Brok explains how missteps during patient support program transitions—ranging from service disruptions to data misalignment—can undermine access, adherence, and brand trust. He describes best practices organizations can use to ensure a smooth transition while protecting patients, providers, and program outcomes.

To learn more, download AssistRx’s Hub Transition Process Checklist. You can also schedule a meeting with the AssistRx team at the Asembia Summit in Las Vegas.

Read on for Brok’s insights.

Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update

By Adam J. Fein, Ph.D.

It's time for Drug Channels Institute’s (DCI) annual update of vertical integration among insurers, PBMs, specialty pharmacies, and healthcare services within U.S. drug channels. As you can see below, we have updated and revised our infamous illustration of the major vertical business relationships within the largest companies.

These organizations continue to exert greater control over patient access, sites of care/dispensing, and pricing, although some have started to unwind their vertical integration strategies. Scrutiny of these companies’ actions continues to grow.

For all the details behind these companies’ operations, check out DCI’s new 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.

Informa Connect’s Life Sciences Pricing & Contracting USA

Informa Connect’s Life Sciences Pricing & Contracting USA
May 18-20, 2026 | Philadelphia, PA

Drug Channels readers save 10% with code 26DRCH10*

Pricing & Contracting USA arrives at an important moment for our industry. As you work to navigate the evolving healthcare landscape, this annual event brings together 70+ expert speakers to lead the critical discussions that will drive comprehensive market strategy, uniting Medicaid, Policy, Pricing, Contracting & Reporting thought leaders.

Event features include:

• Wholesaler/Manufacturer Team-to-Team Meet-and-Greets: Direct industry collaboration led by McKesson and Cencora.


• Executive Programming: Fireside Chats with External Counsel, Closed Door Executive Strategy Summit and Luncheon.


• Interactive Sessions: Speed Networking, AI Lunch and Learn


• Strategic Working Groups: Medicaid Working Group Report, 80 Minute Industry Strategy Working Group.


• The Hottest Topics: Get ready for coverage on Most Favored Nation (MFN) Pricing Implementation, Medicare Part B Drug Negotiations (2028 Launch), 340B Rebate Model from all stakeholder perspectives, State Medicaid Revenue Transparency Sessions, Cell & Gene Therapy Outcomes-Based Contracting, AI-Powered Pricing Scenario Planning, Direct-to-Consumer Pharma Initiatives, Chargeback Data Accuracy Impact on Rebates, What's new with GTN, GPOs, PBMs, PDABs and SPTR, Government Shutdown Policy Timeline Disruption, and so much more.

Featuring 70+ speakers from: Accord, Alkermes, AstraZeneca, Azurity, Chiesi, CMS, CSL Vifor, Genentech, Gilead, GSK, Keenova Therapeutics, Novartis, OIG, PhRMA, Sandoz, UCB and many more.

Join us where Medicaid, Commercial & Government Teams will collaborate to drive a successful market strategy! View the agenda for Pricing & Contracting USA to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/pricing-contracting-usa for further details and to register.

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates or other offers. Other restrictions may apply.

---

The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish an event post on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).